Last reviewed · How we verify
Intravenous Cisplatin & etoposide
Cisplatin and etoposide are chemotherapy agents that work together to damage cancer cell DNA and prevent cell division, leading to cancer cell death.
Cisplatin and etoposide are chemotherapy agents that work together to damage cancer cell DNA and prevent cell division, leading to cancer cell death. Used for Small cell lung cancer, Germ cell tumors, Lymphomas.
At a glance
| Generic name | Intravenous Cisplatin & etoposide |
|---|---|
| Also known as | Control arm, Standard intravenous chemotherapy |
| Sponsor | Swami Rama Cancer Hospital and Research Institute |
| Drug class | Chemotherapy combination (alkylating agent + topoisomerase II inhibitor) |
| Target | DNA (cisplatin: DNA cross-linking; etoposide: topoisomerase II) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin is a platinum-based alkylating agent that forms DNA cross-links, preventing DNA replication and transcription. Etoposide is a topoisomerase II inhibitor that prevents DNA strand rejoining after breakage. The combination exploits complementary mechanisms to maximize cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Small cell lung cancer
- Germ cell tumors
- Lymphomas
- Other solid tumors (indication-dependent based on trial design)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Alopecia
- Mucositis
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
- Secondary malignancy (long-term)
Key clinical trials
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (PHASE2)
- A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma (PHASE1, PHASE2)
- Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma (PHASE3)
- Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (EARLY_PHASE1)
- Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC (PHASE1)
- Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: